On October 4, 2023 Flare Therapeutics Inc., a biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, reported a poster presentation highlighting an artificial intelligence-based model developed in partnership with PathAI that identifies the luminal subtype in Urothelial Carcinoma as a novel biomarker approach for its first-in-class clinical candidate FX-909 at the upcoming 2023 AACR (Free AACR Whitepaper)-NCI-EORTC AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper), taking place October 11-15 in Boston, Massachusetts (Press release, Flare Therapeutics, OCT 4, 2023, View Source [SID1234635661]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details for the poster presentation are as follows:

Abstract Title: AI analysis of histological images accurately identifies luminal subtype urothelial carcinomas characterized by high PPARG expression
Poster Number: B016
Presenter: Stefan Kirov, Vice President, Computational Biology, Flare Therapeutics
Date/Time: Friday, October 13, 2023, from 12:30 to 4:00 p.m. ET
Location: Exhibit Hall D, Hynes Convention Center, Boston

On October 4, 2023 DELFI Diagnostics, Inc., a developer of accessible blood-based tests that deliver a new way to detect cancer, reported that the company will participate in multiple sessions at the HLTH 2023 conference in Las Vegas, Nevada, and the CHEST 2023 Annual Meeting in Honolulu, Hawai’i, both taking place October 8-11, 2023 (Press release, Delfi Diagnostics, OCT 4, 2023, View Source [SID1234635660]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

At HLTH, DELFI will share a critical update on the company’s progress developing its lung cancer detection test for screen-eligible individuals, as well as perspectives on the evolving liquid biopsy landscape during a Tech Talk presentation and a panel discussion. DELFI’s approach to early cancer detection applies advanced machine learning technology to whole-genome sequencing data to compare an individual’s cell-free DNA (cfDNA) patterns and characteristics against populations with and without cancer. An oral presentation at CHEST will highlight new data from the DELFI-L101 Study, "DNA Evaluation of Fragments for Early Interception – Lung Cancer Training Study," a prospective, multicenter, case-control study among individuals eligible for lung cancer screening to train and independently validate the blood-based test for early cancer detection.

"Lung cancer is the leading cause of cancer death globally, yet only six percent of the over 15 million Americans who are eligible to be screened annually do so," said Peter B. Bach, M.D., DELFI Chief Medical Officer, who will participate in a HLTH panel on cancer screening. "DELFI is built to solve the highest-burden population health issues, starting with lung cancer. HLTH and CHEST are timely opportunities for us to reveal new insights on and advancements with our accurate, accessible new way to detect cancer in its earliest stages."

DELFI HLTH Events

Convention Center West Hall, Las Vegas, NV

DELFI Tech Talk: A ‘FirstLook’ at DELFI’s New Way to Detect Early Lung Cancer: 1:30-1:40 pm PDT, Monday, October 9, 2023, Tech Talk Stage. Victor Velculescu, M.D., Ph.D., DELFI Founder and Chief Executive Officer, will deliver a science and technology presentation on the company’s lung cancer early detection test.
"To Screen or Not to Screen" Panel: 2:10-2:50 pm PDT, Tuesday, October 10, 2023, Sky Stage. Dr. Bach will share his perspectives on the current landscape of early cancer detection and how DELFI is developing a new solution to address unmet early detection needs on a population-health scale.
Oral Presentation at CHEST
Hawai’i Convention Center, Honolulu, Hawai’i

Prospective Evaluation of Cell-Free DNA Fragmentation Profiles for Lung Cancer Detection: 12:32–12:36 pm HST, Tuesday, October 10, 2023, Rapid Area 2D. As part of the "Updates in Lung Cancer" session, Peter Mazzone, M.D., MPH, Director of the Lung Cancer Program and Lung Cancer Screening Program for the Respiratory Institute at the Cleveland Clinic and the principal investigator for DELFI’s L101 study, will present new data from the study during an oral presentation.

On October 4, 2023 Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, reported that an abstract involving SNAP-CAR has been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s 38th Annual Meeting (SITC 2023) (Press release, Coeptis Therapeutics, OCT 4, 2023, View Source [SID1234635659]). SITC (Free SITC Whitepaper) 2023 is being held Nov. 1–5, 2023, at San Diego Convention Center in San Diego.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The poster presentation titled, "SNAP CAR T cells for programmable antigen targeting," will detail research involving SNAP-CAR, a "universal" CAR T cell therapy platform that can be adapted to different cancer indications. Licensed by Coeptis from the University of Pittsburgh, SNAP-CAR offers an opportunity to direct the power of CAR T to an array of cancers that have, until now, been inaccessible via current cell therapy technologies by providing a highly programmable antigen targeting platform.

"Having research on SNAP-CAR presented at such a renowned oncology conference as SITC (Free SITC Whitepaper) provides additional validation of the technology’s potential and the exceptional work being conducted by Dr. Lohmueller and his team at the University of Pittsburgh," said Dave Mehalick, President and CEO of Coeptis Therapeutics. "SNAP-CAR represents a powerful technology with the potential to be engineered to address numerous cancers, including HER2-expressing cancer, which we are targeting as our potential first-in-human clinical development program."

About SNAP-CAR
SNAP-CAR, which Coeptis Therapeutics licensed from the University of Pittsburgh, is designed to be a "universal" CAR T cell therapy platform that can be adapted to different cancer indications. Instead of directly binding to a target on the tumor cell, CAR T cells are co-administered with one or more antibody adaptors that bind to the tumor cells and are fitted with a chemical group that irreversibly connects them to the SNAP-CAR on the therapeutic cells via a covalent bond. Pre-clinical studies in mice have demonstrated that by targeting tumors via antibody adaptor molecules, the SNAP-CAR therapy provides a highly programmable therapeutic platform.

On October 4, 2023 Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, reported that Beyond Cancer, Ltd. will present two proffered posters at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper)-National Cancer Institute-European Organisation for Research and Treatment of Cancer (AACR-NCI-EORTC) (Free AACR-NCI-EORTC Whitepaper) AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper) 2023, which is scheduled to be held October 11th – 15th in Boston, Massachusetts (Press release, Beyond Air, OCT 4, 2023, View Source [SID1234635658]). Abstracts are scheduled to be released to AACR (Free AACR Whitepaper)-NCI-EORTC registrants today 12:00 pm U.S. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the Company’s poster presentations are as follows:

Title: Intratumoral Administration of Ultra High-Concentration Nitric Oxide (UNO) and Anti PD-1 Treatment Leads to High Tumor Regression Rates and Prolonged Survival in Tumor-Bearing Mice
Poster number: A078
Session: Poster Session A
Session Date and Time: Thursday, October 12, 2023 / 12:30 pm – 4:00 pm EDT
Session Location: Level 2, Exhibit Hall D
Abstract Number: 35782
Participant: Yana Epshtein, PhD; Head of Translational Science, Beyond Cancer, Ltd.

Title: Ultra-high concentration nitric oxide (UNO) enhances anti-CTLA-4 treatment activity and induces a durable anti-tumor response
Poster number: C080
Session: Poster Session C
Session Date and Time: Saturday, October 14, 2023 / 12:30 pm – 4:00 pm EDT
Session Location: Level 2, Exhibit Hall D
Abstract Number: 35688
Participant: Yogev Sela, PhD; Head of In Vitro Studies, Beyond Cancer, Ltd.

About Nitric Oxide
Nitric Oxide (NO) is a potent molecule, naturally synthesized in the human body, proven to play a critical role in a broad array of biological functions. In the airways, NO targets the vascular smooth muscle cells that surround the small resistance arteries in the lungs. Currently, exogenous inhaled NO is used in adult respiratory distress syndrome, post certain cardiac surgeries and persistent pulmonary hypertension of the newborn to treat hypoxemia. Additionally, NO is believed to play a key role in the innate immune system and in vitro studies suggest that NO possesses anti-microbial activity not only against common bacteria, including both gram-positive and gram-negative, but also against other diverse pathogens.

On October 4, 2023 Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, reported the presentation of preliminary 18-month safety and efficacy data from its ongoing Phase 1/2A clinical trial evaluating the safety, tolerability, and signal of efficacy of Radspherin in patients with peritoneal carcinomatosis from colorectal cancer at the 13th International Congress on Peritoneal Surface Malignancies of the Peritoneal Surface Oncology Group International (PSOGI), to be held at the Palazzo del Cinema in Venice, Italy from October 4 – 6, 2023 (Press release, Oncoinvent, OCT 4, 2023, https://www.oncoinvent.com/press-release/oncoinvent-presents-preliminary-18-month-safety-and-efficacy-data-from-ongoing-rad-18-002-phase-1-2a-trial-of-radspherin-in-colorectal-cancer-patients-at-the-13th-psogi-international-congress-on/ [SID1234635657]). The presentation, titled "18-month safety and efficacy after intraperitoneal treatment with 224Radium-labelled microparticles (Radspherin) after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) for colorectal peritoneal metastasis (PM)" will be presented on October 4, 2023 from 11:55 a.m. to 12:05 p.m. CET (5:55 a.m. EDT).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are thrilled to continue to demonstrate the robust safety and efficacy profile of Radspherin with the presentation of 18-month data at PSOGI. At 18 months, none of the patients administered Radspherin at the recommended dose experienced peritoneal recurrences. Along with a demonstrated robust safety profile, we believe Radspherin has potential as a novel treatment," said Anders Månsson, Chief Executive Officer of Oncoinvent. "These data represent a significant clinical milestone for Radspherin, giving us confidence in its potential to prevent peritoneal recurrence. We look forward to the continued clinical development of this promising therapy."

Details of the oral presentations are as follows:

Oral Presentation Session: Session II Oral Abstract – Colorectal Cancer

Presentation Title: 18-month safety and efficacy after intraperitoneal treatment with 224Radium-labelled microparticles (Radspherin) after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) for colorectal peritoneal metastasis (PM)

Presenting Author: Stein Gunnar Larsen, MD, PhD, Oslo University Hospital, the Norwegian Radium Hospital.

Oral Presentation Date and Time: October 4th, 2023, from 11:55 a.m. to 12:05 p.m. CET (8:05 a.m. EDT)

This Phase 1/2A study is designed to evaluate the safety, tolerability, and signal of efficacy of Radspherin injected intraperitoneally two days after the completion of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC). A dose of 7 MBq was recommended following the completion of dose escalation 1-2-4-7 MBq. A total of 23 patients with peritoneal metastasis from colorectal cancer were enrolled, with 12 receiving the recommended dose of 7MBq. Preliminary safety and survival data at 18-months is presented.

Key results:

At 18 months, none of the 12 patients who received the recommended dose of 7 MBq experienced peritoneal recurrences
Only 2.6% of all adverse events reported were considered to be related to Radspherin, all of which were grade 1-2

Additionally, a poster demonstrating Radspherin as a novel radiopharmaceutical for treatment for peritoneal metastasis will be presented on October 4th, 2023

Poster Presentation Session: Treatment and Prevention of Peritoneal Metastases from Colorectal Cancer

Poster Title: Novel radiopharmaceutical for intraperitoneal treatment of peritoneal metastasis from colorectal and ovarian cancer after complete surgical resection

Presenting Author: Kari Myren, Oncoinvent AS

Poster Presentation Date and Time: October 4th, 2023, from 1:00 p.m. to 1:30 p.m. CET (9:00 a.m. to 9:30 a.m. EDT)